Clinical trial
A Prospective, Controlled Phase II Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib Monotherapy as First - Line Treatment for Locally Advanced or Recurrent Metastatic Non - Squamous NSCLC With EGFR Mutations and High PD-L1 Expression.
NCT06982924 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Controlled Phase II Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib Monotherapy as First - Line Treatment for Locally Advanced or Recurrent Metastatic Non - Squamous NSCLC With EGFR Mutations and High PD-L1 Expression.
- Lead sponsor
- Shanghai Chest Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- June 30, 2025
- Completion date
- December 30, 2028
- Enrollment
- 136 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
egfr mutation positive advanced non small cell lung cancer, pd-l1 positive